<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928092</url>
  </required_header>
  <id_info>
    <org_study_id>HM20019541</org_study_id>
    <nct_id>NCT04928092</nct_id>
  </id_info>
  <brief_title>A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease</brief_title>
  <acronym>Zero-AKI</acronym>
  <official_title>A Zero Acute Kidney Injury (Zero-AKI) Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the outcomes of Percutaneous Coronary Intervention&#xD;
      (PCI) in patients with chronic kidney disease (CKD) using smaller doses of contrast dye that&#xD;
      are validated as being at low risk of causing injury to the kidneys, with the larger doses&#xD;
      that are traditionally used contemporary practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate whether using lower doses of contrast dye leads to lower rates of&#xD;
      kidney injury compared to current standard of care. In particular, effort will be taken to&#xD;
      maintain the total amount of contrast dye below a scientifically-validated threshold&#xD;
      calculated on the basis of each participant renal function. Participants will already be&#xD;
      scheduled to undergo a PCI. Because a smaller amount of contrast dye will be used, an&#xD;
      intravascular ultrasound (IVUS) will be used to help the doctors see and open the blockages&#xD;
      in participant's coronary arteries. IVUS is already used to optimize PCI results, but will be&#xD;
      used more extensively in this case. The amount of contrast dye received will be tailored on&#xD;
      each participant kidney function. Prospectively enrolled patients will be matched with&#xD;
      historical controls who underwent PCI with non-intravascular imaging based approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Kidney Injury (AKI)</measure>
    <time_frame>Up to 72 hours after the procedure</time_frame>
    <description>Standard laboratory assays related to renal function will be used to identify which, if any, patients develop AKI</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cardiac death</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of cardiac deaths</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of myocardial infarctions</description>
  </other_outcome>
  <other_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of target-lesion revascularizations</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of deaths due to any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Pericardial effusion</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of pericardial effusion</description>
  </other_outcome>
  <other_outcome>
    <measure>new need for dialysis</measure>
    <time_frame>Up to 30 days after PCI procedure</time_frame>
    <description>Number of new patients needing dialysis</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Active research group</arm_group_label>
    <description>Patients undergoing intravascular imaging guided, low contrast PCI procedure as part of standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care Ultra Low Contrast PCI</intervention_name>
    <description>PCI using low amounts of contrast media which is standard of care at VCU Medical Center</description>
    <arm_group_label>Active research group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled to undergo a PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients undergoing elective and urgent (i.e., non-emergent) PCI&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  eGFR &lt;60 ml/min/1.73 m2&#xD;
&#xD;
          -  Angina or equivalent and/or documentation of inducible myocardial ischemia&#xD;
&#xD;
          -  Presence of =1 coronary stenosis, evaluated &gt;70% by visual estimation (on a previously&#xD;
             performed coronary angiography) or with an FFR =0.80&#xD;
&#xD;
          -  ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergent PCI due to either hemodynamic instability, ST-elevation myocardial infarction&#xD;
             or sudden cardiac death&#xD;
&#xD;
          -  PCI on chronic total occlusion&#xD;
&#xD;
          -  Prior PCI within 3 weeks&#xD;
&#xD;
          -  Age &gt;90 years&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;20%&#xD;
&#xD;
          -  Need for mechanical circulatory support&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Non-English speaking patients&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Azzalini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenzo Azzalini, MD</last_name>
    <phone>804-628-0713</phone>
    <email>lorenzo.azzalini@vcuhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

